Jul 16, 2017 - Novartis could take the top spot from Pfizer in prescription-drug sales by 2022. So what?
Sep 02, 2017 - If you're scratching your head over Gilead's $11.9 billion acquisition of the cancer-focused biotech, what management had to say about the deal should remove your confusion.
Sep 01, 2017 - Ahead of Gilead Sciences completing its acquisition of CAR-T powerhouse Kite Pharma later this year, Novartis has secured FDA approval for its own CAR-T cancer therapy, and priced it at $475,000.
Aug 10, 2017 - Chicago Bridge & Iron Co. NV (NYSE:CBI)Q2 2017 Earnings CallAugust 09, 2017 5:00 pm ETExecutivesW. Scott Lamb - Chicago Bridge & Iron Co. NVPatrick K. Mullen - Chicago Bridge & Iron Co. NVMichael S. T
Jul 25, 2017 - The first CAR-T therapy recently won a unanimous thumbs up for approval. But that doesn't mean CAR-T stocks are out of the woods just yet.
Aug 27, 2017 - Roche, Novartis, Pfizer, Johnson & Johnson, and Merck are investing the heaviest in R&D. That could bode well for these big pharma stocks.
Sep 07, 2017 - The acquisition of Kite Pharma is a good move, but don't get caught up in the hype of Novartis' approval for Kymriah, which uses the same technology as Kite.
Apr 13, 2017 - A pipeline of drugs has this biotech poised for further success.
Sep 14, 2017 - Ironically, round three could have the companies fighting on the same side.
May 15, 2017 - The first-quarter report saw adjusted earnings holding steady while organic sales increased by 7%.